Metastatic breast cancer, Cancer
OLMAOlema PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for OP-1250 (palazestrant) (CER antagonist) in Metastatic breast cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
OPERA-01 trial. 12/5/23 Trial-in-progress poster presentation at SABCS '23. Clinical sites activated, enrolling w/ first patient dosed in Nov 2023. Trial-in-progress poster at ASCO '24. 5/13/25- Topline data in 2026. 11/10/25:- On track for OPERA-01 topline data in H2 2026. 03/16/26:- OPERA-01 Phase 3 monotherapy trial on track for topline data in fall 2026. 03/17/26:- Present AACR 2026 preclinical poster on palazestrant ER antagonism on April 20, 2026. 04/21/26:- FDA Fast Track designation noted for palazestrant in ER+/HER2- metastatic breast cancer. 05/12/26:- OPERA-01 Phase 3 monotherapy trial remains on track for topline data in fall 2026. 08/10/26:- OPERA-01 enrollment completed; topline data now expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.